Boosting Antitumour Immunity through Targeted Delivery of Interferon-α

Boosting Antitumour Immunity through Targeted Delivery of Interferon-α

Immune checkpoint inhibitors (ICIs) have revolutionised cancer immunotherapy but their success is wholly dependent on amplifying an existing immune response directed against the tumour. A recent study by Tsuchiya et al. suggests how the properties of induced pluripotent stem cells (iPSCs) may be exp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Trends in molecular medicine 2019-11, Vol.25 (11), p.935-937
Hauptverfasser: Fairchild, Paul J., Davies, Timothy J.
Format: Artikel
Sprache:eng
Schlagworte:
dendritic cell
Humans
immune checkpoint inhibitors
Immunotherapy
Interferon-alpha - metabolism
Interferon-alpha - pharmacology
interferon-α
Molecular Targeted Therapy
Neoplasms - immunology
Neoplasms - therapy
Pluripotent Stem Cells - immunology
Pluripotent Stem Cells - metabolism
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Immune checkpoint inhibitors (ICIs) have revolutionised cancer immunotherapy but their success is wholly dependent on amplifying an existing immune response directed against the tumour. A recent study by Tsuchiya et al. suggests how the properties of induced pluripotent stem cells (iPSCs) may be exploited for the targeted delivery of interferon-α (IFNα) to elicit an appropriate response.
ISSN:1471-4914
1471-499X
DOI:10.1016/j.molmed.2019.09.001